Vancomycin Paste and Sternal Wound Infections.

H. Lazar

DOI: https://doi.org/10.1016/j.athoracsur.2017.02.062

Abstract:

What problem does this paper attempt to address?

Rebuilding vascular access: from the viewpoint of mechanics and materials

Aurora Battistella,Morgan Linger,Anh Thy Nguyen,David Madukwe,Prabir Roy-Chaudhury,Wei Tan

DOI: https://doi.org/10.3389/fbioe.2024.1448186

2024-09-04

Abstract:This review presents a comprehensive analysis of vascular access in hemodialysis, focusing on the current modalities, their associated challenges, and recent technological advancements. It closely examines the status of three primary types of vascular access: arteriovenous fistulas, arteriovenous grafts, and central venous catheters. The review delves into the complications and pathologies associated with these access types, emphasizing the mechanobiology-related pathogenesis of arteriovenous access. Furthermore, it explores recent clinical trials, biomaterials, and device innovations, highlighting novel pharmaceutical approaches, advanced materials, device designs, and cutting-edge technologies aimed at enhancing the efficacy, safety, and longevity of vascular access in hemodialysis. This synthesis of current knowledge and emerging trends underscores the dynamic evolution of vascular access strategies and their critical role in improving patient care in hemodialysis.
Hemodialysis Vascular Access: A Historical Perspective on Access Promotion, Barriers, and Lessons for the Future

Anatole Besarab,Stanley Frinak,Suresh Margassery,Jay B Wish

DOI: https://doi.org/10.1016/j.xkme.2024.100871

2024-07-15

Abstract:This review describes the history of vascular access for hemodialysis (HD) over the past 8 decades. Reliable, repeatable vascular access for outpatient HD began in the 1960s with the Quinton-Scribner shunt. This was followed by the autologous Brecia-Cimino radial-cephalic arteriovenous fistula (AVF), which dominated HD vascular access for the next 20 years. Delayed referral and the requirement of 1.5-3 months for AVF maturation led to the development of and increasing dependence on synthetic arteriovenous grafts (AVGs) and tunneled central venous catheters, both of which have higher thrombosis and infection risks than AVFs. The use of AVGs and tunneled central venous catheters increased progressively to the point that, in 1997, the first evidence-based clinical practice guidelines for HD vascular access recommended that they only be used if a functioning AVF could not be established. Efforts to promote AVF use in the United States during the past 2 decades doubled their prevalence; however, recent practice guidelines acknowledge that not all patients receiving HD are ideally suited for an AVF. Nonetheless, improved referral for AVF placement before dialysis initiation and improved conversion of failing AVGs to AVFs may increase AVF use among patients in whom they are appropriate.
Vascular access challenges in hemodialysis patients with superior vena cava syndrome

Rosalinda D'Amico,Andrew Nicoli,Andrei Zdoroveac,Lorenz Gürke,Andrej Isaak

DOI: https://doi.org/10.1177/11297298241227549

2024-02-07

The Journal of Vascular Access

Abstract:The Journal of Vascular Access, Ahead of Print. Background:Superior vena cava syndrome in hemodialysis patients resulting from previous or current use of a tunneled central vein catheter is a rare but potentially severe condition. Two aspects have to be addressed during management and treatment: the restoration of central venous flow and the creation of an alternative vascular access to guarantee hemodialysis.Research design:Conforming to the current guidelines and literature, we present a stepwise approach and discuss therapeutic options. The removal of the tunneled central vein catheter should be attempted and a native vascular access created whenever feasible.Results:First, an upper extremity AVF should be preserved or, as in our case, made functional. Endovascular treatment of CVSO should primarily consist of balloon dilatation. Placement of a stent or stent graft should be considered as a secondary option. HeRO graft placement may be considered in recurrent CVSO and recanalization with a Surfacer. LL-AVF or AVG need to be discussed and may be an alternative for certain HD patients when the risk of lower limb ischemia and infection is considered.Conclusion:Several therapeutic options are available and the basic principles are well established in the literature, although the level of evidence is not high. Therefore, we propose a stepwise and interdisciplinary approach to guide the challenging decision-making process in SVC.

peripheral vascular disease
Global hemodialysis vascular access care: Three decades of evolution

Mohamed Hassanein,Yeshwanter Radhakrishnan,Nora Hernandez Garcilazo,Si Yuan Khor,Sayna Norouzi,Evamaria Anvari,Roman Shingarev,Tushar J Vachharajani

DOI: https://doi.org/10.1177/11297298231159251

2023-04-26

Abstract:The development of vascular access for hemodialysis has come a long way since 1943 when the first hemodialysis treatment was performed in humans by connecting an artery and vein using an external glass canula. Since then, vascular access care has evolved robustly through contributions from numerous countries and professional nephrology societies, worldwide. To understand the global distribution and contribution of different specialties to medical literature on dialysis vascular access care, we performed a literature search from 1991 to 2021 and identified 2768 articles from 74 countries. The majority of publications originated from the United States (41.5%), followed by China (5.1%) and the United Kingdom (4.6%). Our search results comprise of observational studies (43%), case reports/series (27%), review articles (16.5%) and clinical trials (12%). A large proportion of articles were published in Nephrology journals (49%), followed by General Medicine (14%), Surgery (10%), Vascular Medicine (8%), and Interventional Radiology journals (4%). With the introduction of interventional nephrology, nephrologists will be able to assume the majority of the responsibility for dialysis vascular access care and above all maintain a close interdisciplinary collaboration with other specialties to provide optimum patient care. In this review article, we discuss the history, evolving knowledge, challenges, educational opportunities, and future directions of dialysis vascular access care, worldwide.
Arteriovenous Access for Hemodialysis

Charmaine E. Lok,Thomas S. Huber,Ani Orchanian-Cheff,Dheeraj K. Rajan

DOI: https://doi.org/10.1001/jama.2024.0535

IF: 11.816

2024-03-18

JAMA

Abstract:Importance Hemodialysis requires reliable vascular access to the patient’s blood circulation, such as an arteriovenous access in the form of an autogenous arteriovenous fistula or nonautogenous arteriovenous graft. This Review addresses key issues associated with the construction and maintenance of hemodialysis arteriovenous access. Observations All patients with kidney failure should have an individualized strategy (known as Patient Life-Plan, Access Needs, or PLAN) for kidney replacement therapy and dialysis access, including contingency plans for access failure. Patients should be referred for hemodialysis access when their estimated glomerular filtration rate progressively decreases to 15 to 20 mL/min, or when their peritoneal dialysis, kidney transplant, or current vascular access is failing. Patients with chronic kidney disease should limit or avoid vascular procedures that may complicate future arteriovenous access, such as antecubital venipuncture or peripheral insertion of central catheters. Autogenous arteriovenous fistulas require 3 to 6 months to mature, whereas standard arteriovenous grafts can be used 2 to 4 weeks after being established, and “early-cannulation” grafts can be used within 24 to 72 hours of creation. The prime pathologic lesion of flow-related complications of arteriovenous access is intimal hyperplasia within the arteriovenous access that can lead to stenosis, maturation failure (33%-62% at 6 months), or poor patency (60%-63% at 2 years) and suboptimal dialysis. Nonflow complications such as access-related hand ischemia (“steal syndrome”; 1%-8% of patients) and arteriovenous access infection require timely identification and treatment. An arteriovenous access at high risk of hemorrhaging is a surgical emergency. Conclusions and Relevance The selection, creation, and maintenance of arteriovenous access for hemodialysis vascular access is critical for patients with kidney failure. Generalist clinicians play an important role in protecting current and future arteriovenous access; identifying arteriovenous access complications such as infection, steal syndrome, and high-output cardiac failure; and making timely referrals to facilitate arteriovenous access creation and treatment of arteriovenous access complications.

medicine, general & internal
Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency

Gaurav Baranwal,Haseeb Mukhtar,Jamie Kane,Alaura Lemieux,Sanjay Misra

DOI: https://doi.org/10.3390/ijms252312719

IF: 5.6

2024-11-28

International Journal of Molecular Sciences

Abstract:Chronic kidney disease (CKD) affects more than 10% of the world's population. Hemodialysis, along with peritoneal dialysis and renal transplant, is one of the renal replacement therapies offered to patients with CKD/end-stage renal disease (ESRD). To proceed with hemodialysis, vascular access is required. The two means of long-term access are arteriovenous fistula (AVF) and arteriovenous graft (AVG). Multiple therapies have been created to help the long-term patency of AVFs. These therapies are needed as 40% of AVFs fail within the first year and additional intervention is required. Much of the existing research has focused on biomarkers, immune cells, hypoxia, and cell-based therapies. Regeneration therapy using mesenchymal stem cells seeks to investigate other ways that we can treat AVF failure. Mesenchymal stem cells are harvested as two main types, fetal and adult. Fetal cells are harvested at different times in fetal gestation and from multiple sources, placental blood, Whartons jelly, and amniotic stem cell fluid. Taken together, this review summarizes the different preclinical/clinical studies conducted using different types of MSCs towards vascular regenerative medicine and further highlights its potential to be a suitable alternative approach to enhance AVF patency.

biochemistry & molecular biology,chemistry, multidisciplinary
Alternative dialysis access strategies: A case report of a patient with transrenal hemodialysis catheter due to exhausted traditional routes and review of literature

Maysam Shehab,Igal Griton,Stanislav Kosykh,Adi R Bachar,Menashe Haddad,Ilan Rozenberg

DOI: https://doi.org/10.1177/11297298231220534

2024-01-13

The Journal of Vascular Access

Abstract:The Journal of Vascular Access, Ahead of Print. Vascular access is the primary lifeline for patients with end-stage renal disease. While arteriovenous fistulas and grafts are the conventionally favored methods for dialysis therapy, certain patients may deplete these traditional vascular access options due to various reasons. In the quest for alternatives, unconventional vascular pathways could be considered, including transhepatic, trans-lumbar and trans-renal approaches. We present a case of a 61-year-old male who exhausted all the traditional vascular access options, therefore trans-renal hemodialysis catheter placement was performed. Overall, this case highlights the challenges of securing a reliable vascular access to perform dialysis therapy and implementing unconventional methods whenever regular means are exhausted.

peripheral vascular disease
Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review

Andrea K. Viecelli,Emma O’Lone,Benedicte Sautenet,Jonathan C. Craig,Allison Tong,Eric Chemla,Lai-Seong Hooi,Timmy Lee,Charmaine Lok,Kevan R. Polkinghorne,Robert R. Quinn,Tushar Vachharajani,Raymond Vanholder,Li Zuo,Ashley B. Irish,Trevor A. Mori,Elaine M. Pascoe,David W. Johnson,Carmel M. Hawley

DOI: https://doi.org/10.1053/j.ajkd.2017.09.018

IF: 11.072

2018-01-01

American Journal of Kidney Diseases

Abstract:BACKGROUND:Many randomized controlled trials have been performed with the goal of improving outcomes related to hemodialysis vascular access. If the reported outcomes are relevant and measured consistently to allow comparison of interventions across trials, such trials can inform decision making. This study aimed to assess the scope and consistency of vascular access outcomes reported in contemporary hemodialysis trials.STUDY DESIGN:Systematic review.SETTING & POPULATION:Adults requiring maintenance hemodialysis.SELECTION CRITERIA:All randomized controlled trials and trial protocols reporting vascular access outcomes identified from ClinicalTrials.gov, Embase, MEDLINE, and the Cochrane Kidney and Transplant Specialized Register from January 2011 to June 2016.INTERVENTIONS:Any hemodialysis-related intervention.OUTCOMES:The frequency and characteristics of vascular access outcome measures were analyzed and classified.RESULTS:From 168 relevant trials, 1,426 access-related outcome measures were extracted and classified into 23 different outcomes. The 3 most common outcomes were function (136 [81%] trials), infection (63 [38%]), and maturation (31 [18%]). Function was measured in 489 different ways, but most frequently reported as "mean access blood flow (mL/min)" (37 [27%] trials) and "number of thromboses" (30 [22%]). Infection was assessed in 136 different ways, with "number of access-related infections" being the most common measure. Maturation was assessed in 44 different ways at 15 different time points and most commonly characterized by vein diameter and blood flow. Patient-reported outcomes, including pain (19 [11%]) and quality of life (5 [3%]), were reported infrequently. Only a minority of trials used previously standardized outcome definitions.LIMITATIONS:Restricted sampling frame for feasibility and focus on contemporary trials.CONCLUSIONS:The reporting of access outcomes in hemodialysis trials is very heterogeneous, with limited patient-reported outcomes and infrequent use of standardized outcome measures. Efforts to standardize outcome reporting for vascular access are critical to optimizing the comparability, reliability, and value of trial evidence to improve outcomes for patients requiring hemodialysis.
Future research directions to improve fistula maturation and reduce access failure

Haidi Hu,Sandeep Patel,Jesse J Hanisch,Jeans M Santana,Takuya Hashimoto,Hualong Bai,Tambudzai Kudze,Trenton R Foster,Jianming Guo,Bogdan Yatsula,Janice Tsui,Alan Dardik

DOI: https://doi.org/10.1053/j.semvascsurg.2016.08.005

Abstract:With the increasing prevalence of end-stage renal disease, there is a growing need for hemodialysis. Arteriovenous fistulae (AVF) are the preferred type of vascular access for hemodialysis, but maturation and failure continue to present significant barriers to successful fistula use. AVF maturation integrates outward remodeling with vessel wall thickening in response to drastic hemodynamic changes in the setting of uremia, systemic inflammation, oxidative stress, and pre-existent vascular pathology. AVF can fail due to both failure to mature adequately to support hemodialysis and development of neointimal hyperplasia that narrows the AVF lumen, typically near the fistula anastomosis. Failure due to neointimal hyperplasia involves vascular cell activation and migration and extracellular matrix remodeling with complex interactions of growth factors, adhesion molecules, inflammatory mediators, and chemokines, all of which result in maladaptive remodeling. Different strategies have been proposed to prevent and treat AVF failure based on current understanding of the modes and pathology of access failure; these approaches range from appropriate patient selection and use of alternative surgical strategies for fistula creation, to the use of novel interventional techniques or drugs to treat failing fistulae. Effective treatments to prevent or treat AVF failure require a multidisciplinary approach involving nephrologists, vascular surgeons, and interventional radiologists, careful patient selection, and the use of tailored systemic or localized interventions to improve patient-specific outcomes. This review provides contemporary information on the underlying mechanisms of AVF maturation and failure and discusses the broad spectrum of options that can be tailored for specific therapy.
The Role of Cardio-Renal Inflammation in Deciding the Fate of the Arteriovenous Fistula in Haemodialysis Therapy

Jamie Kane,Alaura Lemieux,Gaurav Baranwal,Sanjay Misra

DOI: https://doi.org/10.3390/cells13191637

IF: 6

2024-10-02

Cells

Abstract:Vascular access is an indispensable component of haemodialysis therapy for end-stage kidney disease patients. The arteriovenous fistula (AVF) is most common, but importantly, two-year failure rates are greater than fifty percent. AVF failure can occur due to a lack of suitable vascular remodelling, and inappropriate inflammation preventing maturation, or alternatively neointimal hyperplasia and vascular stenosis preventing long-term use. A comprehensive mechanistic understanding of these processes is still lacking, but recent studies highlight an essential role for inflammation from uraemia and the AVF itself. Inflammation affects each cell in the cascade of AVF failure, the endothelium, the infiltrating immune cells, and the vascular smooth muscle cells. This review examines the role of inflammation in each cell step by step and the influence on AVF failure. Inflammation resulting in AVF failure occurs initially via changes in endothelial cell activation, permeability, and vasoprotective chemokine secretion. Resultingly, immune cells can extravasate into the subendothelial space to release inflammatory cytokines and cause other deleterious changes to the microenvironment. Finally, all these changes modify vascular smooth muscle cell function, resulting in excessive and unchecked hyperplasia and proliferation, eventually leading to stenosis and the failure of the AVF. Finally, the emerging therapeutic options based off these findings are discussed, including mesenchymal stem cells, small-molecule inhibitors, and far-infrared therapies. Recent years have clearly demonstrated a vital role for inflammation in deciding the fate of the AVF, and future works must be centred on this to develop therapies for a hitherto unacceptably underserved patient population.

cell biology
Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer, Part 2.

Malcolm A. Smith,J. Dancey,E. Matczak,J. Zwiebel,D. Anderson,M. Schoenfeldt

2002-03-01

Oncology

Abstract:
Case Report: Vascular access in paediatric haemodialysis patients—creating and maintaining the patency of an arteriovenous fistula

Ramona Stroescu,Serban Comsa,Flavia Chisavu,Mihai Gafencu

DOI: https://doi.org/10.3389/fsurg.2024.1181802

IF: 1.8

2024-03-19

Frontiers in Surgery

Abstract:Introduction Paediatric vascular access is a demanding field. The need for a multidisciplinary team is mandatory in children with end-stage kidney disease (ESKD). Central venous catheters (CVCs) remain the preferred option worldwide. Recent emerging data demonstrated the benefits of using arteriovenous fistulas (AVFs) in the paediatric population for long-term vascular access. The small vessel size in children represents a surgical challenge for vascular access. Case presentation We report three cases from our haemodialysis department and the difficulty in maintaining permanent vascular access. The first case is an adolescent girl who required a change in vascular approach after multiple central venous catheter (CVC) infections and catheter thrombosis secondary to thrombophilia. Three AVFs were performed but failure occurred early. The patient was also diagnosed with a complex vascular thrombosis with total occlusion of the inferior vena cava and completed distal thrombosis of the superior vena cava. A permanent CVC was placed in the right jugular vein with the tip in the azygos vein. The second case is of an adolescent boy with systemic vasculitis with multiple CVC infections secondary to immunosuppression. The first thrombosis of two right AVFs occurred early with the development of a pseudo-aneurysm that required surgical intervention. The left brachial-cephalic fistula required surgery for closing the collaterals, repositioning and superficialisation. The third case is an adolescent boy with one surgical stage brachial-basilic left AVF and difficulties in venous puncturing. Conclusion Vascular access in paediatric haemodialysis remains a demanding field. There is a need for a multidisciplinary team, consisting of a vascular surgeon and an interventional radiologist specialising in children.

surgery
Common hemodialysis vascular access for the elderly and their application

Yan WANG,Wei-Hong ZHAO

DOI: https://doi.org/10.3724/SP.J.1264.2014.00035

2014-01-01

Chinese Journal of Multiple Organ Diseases in the Elderly

Abstract:With the number of uremic patients rapidly growing, hemodialysis has been one of important options for the elderly patients with renal failure. The establishment and maintenance of optimal vascular access (VA) is an essential precondition for successful hemodialysis. However, the elderly presents major challenges than the youth in terms of both timing and type of access due to high prevalence of comorbidities, shortened life expectancy, and reduced quality of life. This study focused on the characteristics of vessels in the elderly, elucidated the differences between the elderly and youth in the use of central venous catheter, autologous arteriovenous fistula and vascular graft fistula, and then analyzed the option of vascular access for the elderly.
Effectiveness of Anma massage therapy in alleviating physical symptoms in outpatients with Parkinson's disease: a before-after study.

Nozomi Donoyama,Sachie Suoh,N. Ohkoshi

DOI: https://doi.org/10.1016/j.ctcp.2014.07.010

IF: 3.577

2014-11-01

Complementary Therapies in Clinical Practice

Abstract:
Erratum to: Total Polyphenols, Antioxidant and Antimicrobial Activity of Leaves and Stem Bark Extracts of Allophylus cobbe (L.) Raeusch

Gireesh M Ankad,V. Upadhya,S. Pai,H. Hegde,Subarna Roy,S. Kholkute

DOI: https://doi.org/10.1007/s40011-014-0424-6

2016-09-01

Abstract:
Effect of a ganglionic blocking agent on the orthostatic response in the rat.

C. T. Liu,K. Anderson,H. Lape,F. Rosenberg

1967-06-01

Abstract:
Arteriovenous fistula cannulation in hemodialysis: A vascular access clinical practice guidelines narrative review

Rui Pinto,Clemente Sousa,Anabela Salgueiro,Isabel Fernandes

DOI: https://doi.org/10.1177/11297298211006972

Abstract:The cannulation of an arteriovenous fistula (AVF) by the hemodialysis (HD) nurse is challenging. Despite it being the focus of extensive research, it is still one of the majors causes of damage making it prone to failure. A considerable number of Clinical Practice Guidelines (CPGs) for the management of vascular access (VA) have been published worldwide over the past two decades. This review aimed to assess all information available in the selected CPG regarding AVF cannulation for HD providing a comprehensive analysis in order to interpret possible future cannulation approaches. A total of seven CPGs were described in a coding table separated in seven subthemes: Initiation of cannulation, preparation, technique, needle selection, surveillance, pain, and education. Our analysis outlines current CPGs for HD VA cannulation with lack of good evidence support for the majority of the recommendations, showing that, there is an urgent need for international collaboration and coordination to ensure relevant and high-quality evidence. Future CPGs must consider recommendations with better grading of evidence aiming patient-centered care and nurse decision models that can potentially represent better AVF cannulation outcomes.
Selection of vascular access after autologous arteriovenous fistula failure

Fangping Lu

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2015.17.004

2015-01-01

Abstract:Arteriovenous fistula failure (AVF) is a common complication of vascular access in patients on hemodialysis. Once AVF fails, we face a further selection of vascular access. Currently there are 8 techniques to resolve this problem, such as percutaneous transluminal angioplasty, venous neointimal hyperplasia (VNH) stripping/AVF reconstruction, AVF reconstruction proximal to the original fistula, creation of a new AVF, arteriovenous graft, central vein catheter, surgical thrombectomy, and vascular bypass operation using venous fistula. Principally, in order to protect the resources of blood vessels and increase the proportion of AVF use, we must do our best to repair AVF if possible. Taking into comprehensive consideration, we should give exclusive priority to repair surgically, followed by the percutaneous transluminal angiography (PTA). Other choices should be based on the patient's specific situation.
Progressive increase in vascular access blood flow after percutaneous transluminal angioplasty in patients on hemodialysis

Hyun Jin Koh,Seung-Jung Kim,Shina Lee

DOI: https://doi.org/10.1097/md.0000000000038408

IF: 1.6

2024-06-01

Medicine

Abstract:Successful maintenance of vascular access is a key factor in the quality and longevity of life of patients with end-stage kidney disease (ESKD) receiving hemodialysis. However, many patients experience vascular access dysfunction, such as stenotic or thrombosed arteriovenous fistulas (AVF) and arteriovenous grafts (AVG). Percutaneous transluminal angioplasty (PTA) has become the gold standard treatment for venous stenosis associated with AVFs and AVGs with excellent success rates. [ 1 ]

medicine, general & internal
Invited Commentary Invited Commentary: Assessing Treatment Effects by Using Observational Analyses—Opportunities and Limitations

Philip S. Wang,M. Schoenbaum

Abstract:Making decisions about medical treatments based upon valid evidence is critical to improve health-care quality, outcomes, and value. Although such research commonly connotes the use of randomized controlled trials, experimental methods are not always feasible, and research using observational, quasi-experimental, and other nonexperimental methods may also be important. At the same time, nonexperimental methods are inherently susceptible to various types of bias and thus present special challenges in the search for valid and generalizable evidence. The study by Gardarsdottir et al. (Am J Epidemiol. 2009;170(3):280–285), on which this commentary is based, addresses a key potential source of bias—mismeasurement of patients’ duration of treatment—in previous research on pharmacotherapy for depression. However, the authors’ study is unlikely to address other potential sources of bias, which may make interpretation of their findings more difficult.

Vancomycin Paste and Sternal Wound Infections.

Rebuilding vascular access: from the viewpoint of mechanics and materials

Hemodialysis Vascular Access: A Historical Perspective on Access Promotion, Barriers, and Lessons for the Future

Vascular access challenges in hemodialysis patients with superior vena cava syndrome

Global hemodialysis vascular access care: Three decades of evolution

Arteriovenous Access for Hemodialysis

Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency

Alternative dialysis access strategies: A case report of a patient with transrenal hemodialysis catheter due to exhausted traditional routes and review of literature

Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review

Future research directions to improve fistula maturation and reduce access failure

The Role of Cardio-Renal Inflammation in Deciding the Fate of the Arteriovenous Fistula in Haemodialysis Therapy

Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer, Part 2.

Case Report: Vascular access in paediatric haemodialysis patients—creating and maintaining the patency of an arteriovenous fistula

Common hemodialysis vascular access for the elderly and their application

Effectiveness of Anma massage therapy in alleviating physical symptoms in outpatients with Parkinson's disease: a before-after study.

Erratum to: Total Polyphenols, Antioxidant and Antimicrobial Activity of Leaves and Stem Bark Extracts of Allophylus cobbe (L.) Raeusch

Effect of a ganglionic blocking agent on the orthostatic response in the rat.

Arteriovenous fistula cannulation in hemodialysis: A vascular access clinical practice guidelines narrative review

Selection of vascular access after autologous arteriovenous fistula failure

Progressive increase in vascular access blood flow after percutaneous transluminal angioplasty in patients on hemodialysis

Invited Commentary Invited Commentary: Assessing Treatment Effects by Using Observational Analyses—Opportunities and Limitations